A detailed history of Pinnacle Associates LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Pinnacle Associates LTD holds 266,041 shares of BMY stock, worth $15.7 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
266,041
Previous 195,136 36.34%
Holding current value
$15.7 Million
Previous $8.1 Million 69.9%
% of portfolio
0.22%
Previous 0.13%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$39.66 - $51.75 $2.81 Million - $3.67 Million
70,905 Added 36.34%
266,041 $13.8 Million
Q2 2024

Jul 30, 2024

SELL
$40.25 - $52.99 $246,370 - $324,351
-6,121 Reduced 3.04%
195,136 $8.1 Million
Q1 2024

Apr 26, 2024

SELL
$47.98 - $54.4 $3.11 Million - $3.52 Million
-64,784 Reduced 24.35%
201,257 $10.9 Million
Q4 2023

Jan 19, 2024

SELL
$48.48 - $57.85 $7 Million - $8.35 Million
-144,388 Reduced 35.18%
266,041 $13.7 Million
Q3 2023

Oct 23, 2023

SELL
$57.89 - $64.73 $600,203 - $671,120
-10,368 Reduced 2.46%
410,429 $23.8 Million
Q2 2023

Jul 26, 2023

BUY
$63.71 - $70.74 $9.96 Million - $11.1 Million
156,281 Added 59.08%
420,797 $26.9 Million
Q1 2023

May 04, 2023

SELL
$65.71 - $74.53 $58,481 - $66,331
-890 Reduced 0.34%
264,516 $18.3 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $17,667 - $20,921
-258 Reduced 0.1%
265,406 $19.1 Million
Q4 2022

Jan 25, 2023

SELL
$68.48 - $81.09 $168,255 - $199,238
-2,457 Reduced 0.92%
265,664 $0
Q3 2022

Oct 31, 2022

SELL
$0.13 - $76.84 $910 - $538,417
-7,007 Reduced 2.55%
268,121 $19.1 Million
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $138,341 - $152,361
1,905 Added 0.7%
275,128 $21.2 Million
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $1.12 Million - $1.35 Million
-18,257 Reduced 6.26%
273,223 $20 Million
Q4 2021

Feb 02, 2022

SELL
$53.63 - $62.52 $807,667 - $941,551
-15,060 Reduced 4.91%
291,480 $18.2 Million
Q3 2021

Oct 19, 2021

SELL
$59.17 - $69.31 $782,937 - $917,109
-13,232 Reduced 4.14%
306,540 $18.1 Million
Q2 2021

Aug 02, 2021

SELL
$61.91 - $67.42 $753,568 - $820,636
-12,172 Reduced 3.67%
319,772 $21.4 Million
Q1 2021

May 12, 2021

SELL
$59.34 - $66.74 $830 - $934
-14 Reduced -0.0%
331,944 $21 Million
Q4 2020

Jan 26, 2021

SELL
$57.74 - $65.43 $1.3 Million - $1.47 Million
-22,539 Reduced 6.36%
331,958 $20.6 Million
Q3 2020

Oct 23, 2020

BUY
$57.43 - $63.64 $1.11 Million - $1.23 Million
19,299 Added 5.76%
354,497 $21.4 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $28,396 - $33,198
-518 Reduced 0.15%
335,198 $19.7 Million
Q1 2020

May 13, 2020

BUY
$46.4 - $67.43 $1.41 Million - $2.05 Million
30,334 Added 9.93%
335,716 $18.7 Million
Q4 2019

Feb 03, 2020

BUY
$49.21 - $64.19 $3.26 Million - $4.26 Million
66,303 Added 27.73%
305,382 $19.6 Million
Q3 2019

Nov 08, 2019

BUY
$42.77 - $50.71 $186,263 - $220,842
4,355 Added 1.86%
239,079 $12.1 Million
Q2 2019

Aug 05, 2019

SELL
$44.62 - $49.34 $157,999 - $174,712
-3,541 Reduced 1.49%
234,724 $10.6 Million
Q1 2019

May 10, 2019

BUY
$45.12 - $53.8 $442,897 - $528,100
9,816 Added 4.3%
238,265 $11.4 Million
Q4 2018

Feb 05, 2019

SELL
$48.76 - $63.23 $593,409 - $769,509
-12,170 Reduced 5.06%
228,449 $11.9 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $271,810 - $306,581
-4,925 Reduced 2.01%
240,619 $14.9 Million
Q2 2018

Aug 08, 2018

BUY
$50.53 - $62.98 $59,170 - $73,749
1,171 Added 0.48%
245,544 $13.6 Million
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $36,551 - $42,077
610 Added 0.25%
244,373 $15.5 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $548,870 - $598,409
9,157 Added 3.9%
243,763 $14.9 Million
Q3 2017

Nov 13, 2017

SELL
$55.23 - $63.74 $2.08 Million - $2.4 Million
-37,618 Reduced 13.82%
234,606 $15 Million
Q2 2017

Aug 09, 2017

BUY
N/A
272,224
272,224 $15.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.